drugset / Trial / NCT00252876
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesaglitazar | Small molecule | 1 mg | Oral |